ICER, CADTH, and NICE collaborate to increase transparency in health technology evaluations
The Institute for Clinical and Economic Review (ICER), the Canadian Agency for Drugs and Technologies in Health (CADTH), and the UK’s National Institute for Health and Care Excellence (NICE) have announced changes to the way confidential information about health technologies is handled. The aim is to streamline processes and increase transparency while balancing the need to protect confidential information. The three organizations have been working together to create a more consistent approach to handling clinical data. ICER has updated its academic-in-confidence data policy, reducing the period during which data is redacted from external and public documents from 18 months to 12 months. These changes will come into effect in May 2023.
Recent Posts
Provisional Agreement on EU Pharmaceutical Reform: Boosting Innovation and Combatting Antimicrobi...
Provisional Deal Ushers in EU Pharmaceutical Reform
The European Parliament and Council have reached a provisional agreement to overhaul the EU's pharmaceutical policy framework, marking a major step in the EU Pharmaceutical Refor...
AI Governance Pharmaceuticals: Ensuring Ethical AI Integration in the Medicines Lifecycle
In the pharmaceutical industry, AI governance in pharmaceuticals is crucial for harnessing artificial intelligence's potential in drug discovery, clinical trials, and patient monitoring. How can pharma companies integrate AI ethically across the medicines lifecycle? This article draws on a recent...
2025 China Drug Catalog Boosts Access with 114 New Drugs and Innovative Solutions
Expansion of Coverage in the 2025 National Basic Medical Insurance Drug Catalog
In this update we highlight updates and implications of the 2025 National Basic Medical Insurance Drug Catalog in China's ...